Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

38.94USD
18 May 2018
Change (% chg)

$-0.09 (-0.23%)
Prev Close
$39.03
Open
$39.30
Day's High
$39.44
Day's Low
$38.68
Volume
38,826
Avg. Vol
48,179
52-wk High
$68.57
52-wk Low
$31.00

Latest Key Developments (Source: Significant Developments)

Joseph Darling Named CEO And Director Of Anika Therapeutics
Monday, 5 Mar 2018 04:02pm EST 

March 5 (Reuters) - Anika Therapeutics Inc ::JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS.ANIKA THERAPEUTICS - DARLING TO SUCCEED CHARLES SHERWOOD, WHO WILL RETIRE AS CEO AND A DIRECTOR OF ANIKA ON MARCH 9, 2018.  Full Article

Anika Q4 Earnings Per Share $0.53
Wednesday, 21 Feb 2018 04:05pm EST 

Feb 21 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.53.Q4 REVENUE $29.4 MILLION VERSUS $28.7 MILLION.COMPANY EXPECTS TOTAL REVENUE GROWTH TO BE AROUND MID-SINGLE DIGIT PERCENTAGE RANGE FOR FULL YEAR OF 2018.  Full Article

Anika reports Q3 earnings per share $0.46
Wednesday, 25 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Wednesday, 25 Oct 2017 04:04pm EDT 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article

Anika Therapeutics announces regulatory approval for Monovisc® in Australia
Monday, 16 Oct 2017 04:05pm EDT 

Oct 17 (Reuters) - Anika Therapeutics Inc :Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints.Anika Therapeutics Inc - ‍Anika intends to further expand Monovisc into additional international markets in 2018​.  Full Article

Anika announces appointment of Joseph Darling as president
Thursday, 27 Jul 2017 08:05am EDT 

July 27 (Reuters) - Anika Therapeutics Inc :Anika announces appointment of joseph darling as president.Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo.  Full Article

Anika reports Q2 earnings per share $0.76
Wednesday, 26 Jul 2017 04:05pm EDT 

July 26 (Reuters) - Anika Therapeutics Inc :Anika reports strong second quarter 2017 financial results.Q2 earnings per share $0.76.Q2 revenue $33.5 million versus I/B/E/S view $27.2 million.Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.Anika Therapeutics Inc says company plans to expand into India, Australia, and New Zealand over next six to nine months.Anika Therapeutics Inc says receiving regulatory approval for Monovisc in India for treatment of pain associated with osteoarthritis of all human synovial joints.  Full Article

Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc
Monday, 17 Jul 2017 04:05pm EDT 

July 17 (Reuters) - Anika Therapeutics Inc :Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc.Sees Q2 2017 revenue up 23 to 26 percent.Anika - Milestone payment triggered by Monovisc achieving $100 million in U.S. end-user sales within consecutive 12-month period at end of June.Anika Therapeutics Inc - Company will recognize milestone payment as revenue in Q2 of 2017.Q2 revenue view $27.2 million -- Thomson Reuters I/B/E/S.  Full Article

Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018
Thursday, 25 May 2017 01:30pm EDT 

May 25 (Reuters) - Anika Therapeutics Inc ::Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis.Anika expects to complete supplemental phase III trial in 2018 and anticipates FDA approval in following year.  Full Article

Anika Therapeutics reports Q1 earnings per share $0.37
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Anika Therapeutics Inc :Anika reports first quarter 2017 financial results.Q1 earnings per share $0.37.Q1 revenue $23.4 million versus i/b/e/s view $23.9 million.Q1 earnings per share view $0.38 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Anika Therapeutics Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S